INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zimmer Biomet Holdings, Inc. - ZBH

Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Zimmer Biomet and its executives [1] - Zimmer Biomet reported third-quarter 2025 net sales of $2 billion, which fell short of the consensus estimate of $2.01 billion [2] - The company revised its full-year organic revenue growth outlook down to a range of 3.5% to 4%, from a previous range of 3.5% to 4.5% [2] - Weakness in international markets and non-core businesses, along with order cancellations in the Middle East and Eastern Europe, negatively impacted results [2] - The stock price of Zimmer Biomet dropped by $15.63 per share, or 15.5%, closing at $87.55 on November 5, 2025, following the earnings announcement [2]